Needham & Company Maintains Bullish Stance on Alnylam Pharmaceuticals (ALNY) as Data Suggest Patisiran Clinical Benefit in FAP Patients
Tweet Send to a Friend
Needham & Company analyst Alan Carr reiterated a Buy rating and $94 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
